Enveric Biosciences (STU:SLZ) EV-to-EBIT : 0.37 (As of May. 13, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Enveric Biosciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Enveric Biosciences's Enterprise Value is €-3.32 Mil. Enveric Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was €-8.95 Mil. Therefore, Enveric Biosciences's EV-to-EBIT for today is 0.37.

The historical rank and industry rank for Enveric Biosciences's EV-to-EBIT or its related term are showing as below:

STU:SLZ' s EV-to-EBIT Range Over the Past 10 Years
Min: -15.7 Med: -0.04 Max: 0.41
Current: 0.39

During the past 13 years, the highest EV-to-EBIT of Enveric Biosciences was 0.41. The lowest was -15.70. And the median was -0.04.

STU:SLZ's EV-to-EBIT is ranked better than
80% of 480 companies
in the Biotechnology industry
Industry Median: 5.905 vs STU:SLZ: 0.39

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Enveric Biosciences's Enterprise Value for the quarter that ended in Dec. 2024 was €1.16 Mil. Enveric Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was €-8.95 Mil. Enveric Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -774.84%.

Enveric Biosciences EV-to-EBIT Historical Data

The historical data trend for Enveric Biosciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enveric Biosciences EV-to-EBIT Chart

Enveric Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EV-to-EBIT

Get a 7-Day Free Trial

-6.23

-0.23

0.62

-0.07

-0.15

Enveric Biosciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EV-to-EBIT	Get a 7-Day Free Trial															-0.07	-0.06	-0.12	-0.11	-0.15

Competitive Comparison of Enveric Biosciences's EV-to-EBIT

For the Biotechnology subindustry, Enveric Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enveric Biosciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enveric Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Enveric Biosciences's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Enveric Biosciences EV-to-EBIT Calculation

Enveric Biosciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	-3.315	/	-8.95
	=	0.37

Enveric Biosciences's current Enterprise Value is €-3.32 Mil.
Enveric Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-8.95 Mil.

Enveric Biosciences (STU:SLZ) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Enveric Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2024 )	=	EBIT	/	Enterprise Value (Q: Dec. 2024 )
	=	-8.95	/	1.155079322
	=	-774.84 %

Enveric Biosciences's Enterprise Value for the quarter that ended in Dec. 2024 was €1.16 Mil.
Enveric Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-8.95 Mil.

Enveric Biosciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Enveric Biosciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Enveric Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enveric Biosciences Inc (STU:SLZ) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

ENVB:USA

Address

4851 Tamiami Trail N, Suite 200, Naples, FL, USA, 34103

Website

https://www.enveric.com

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.